AKBA
Income statement / Annual
Last year (2023), Akebia Therapeutics, Inc.'s total revenue was $194.62 M,
a decrease of 33.49% from the previous year.
In 2023, Akebia Therapeutics, Inc.'s net income was -$51.93 M.
See Akebia Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$194.62 M |
$292.60 M |
$213.58 M |
$295.31 M |
$335.00 M |
$207.74 M |
$177.98 M |
$1.54 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$74.15 M
|
$84.80 M
|
$153.39 M
|
$295.91 M
|
$145.34 M
|
$7.69 M
|
$617,000.00
|
$115.79 M
|
$96,000.00
|
$23.26 M
|
| Gross Profit |
$120.47 M
|
$207.81 M
|
$60.18 M
|
-$601,000.00
|
$189.67 M
|
$200.06 M
|
$177.37 M
|
-$114.25 M
|
-$96,000.00
|
-$23.26 M
|
| Gross Profit Ratio |
0.62
|
0.71
|
0.28
|
-0
|
0.57
|
0.96
|
1
|
-74.43
|
0
|
0
|
| Research and Development Expenses |
$63.08 M
|
$129.11 M
|
$147.85 M
|
$218.49 M
|
$322.97 M
|
$291.07 M
|
$230.89 M
|
$115.79 M
|
$43.02 M
|
$25.40 M
|
| General & Administrative Expenses |
$0.00
|
$141.87 M
|
$177.65 M
|
$157.36 M
|
$152.98 M
|
$87.13 M
|
$27.01 M
|
$22.21 M
|
$18.50 M
|
$12.54 M
|
| Selling & Marketing Expenses |
$100.23 M
|
-$3.18 M
|
$174.16 M
|
$153.95 M
|
$149.46 M
|
$87.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$100.23 M
|
$141.87 M
|
$174.16 M
|
$153.95 M
|
$149.46 M
|
$87.06 M
|
$27.01 M
|
$22.21 M
|
$18.50 M
|
$12.54 M
|
| Other Expenses |
$3.42 M
|
-$12.54 M
|
$3.49 M
|
$3.41 M
|
$3.53 M
|
$6.24 M
|
$204,000.00
|
-$188,000.00
|
$287,000.00
|
$700,000.00
|
| Operating Expenses |
$166.73 M
|
$270.99 M
|
$325.50 M
|
$375.84 M
|
$475.95 M
|
$378.20 M
|
$257.90 M
|
$138.00 M
|
$61.51 M
|
$37.94 M
|
| Cost And Expenses |
$240.88 M
|
$355.78 M
|
$478.90 M
|
$671.75 M
|
$621.29 M
|
$385.88 M
|
$257.90 M
|
$138.00 M
|
$61.51 M
|
$37.94 M
|
| Interest Income |
$0.00
|
$15.69 M
|
$19.95 M
|
$8.92 M
|
$2.19 M
|
$6.15 M
|
$2.80 M
|
$901,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$6.03 M
|
$15.69 M
|
$19.94 M
|
$8.87 M
|
$1.40 M
|
$6.15 M
|
$0.00
|
$0.00
|
$510,000.00
|
$206,000.00
|
| Depreciation & Amortization |
$37.63 M
|
$35.28 M
|
$36.13 M
|
$33.59 M
|
$36.42 M
|
$2.42 M
|
$617,000.00
|
$296,000.00
|
$96,000.00
|
$49,000.00
|
| EBITDA |
-$6.87 M |
-$43.26 M |
-$225.96 M |
-$341.00 M |
-$247.64 M |
-$178.09 M |
-$76.06 M |
-$136.16 M |
-$61.42 M |
-$37.89 M |
| EBITDA Ratio |
-0.04
|
-0.16
|
-1.24
|
-1.27
|
-0.85
|
-0.86
|
-0.45
|
-88.71
|
0
|
0
|
| Operating Income Ratio |
-0.24
|
-0.22
|
-1.24
|
-1.27
|
-0.85
|
-0.86
|
-0.45
|
-88.9
|
0
|
0
|
| Total Other Income/Expenses Net |
-$5.67 M
|
-$13.45 M
|
-$17.52 M
|
-$5.63 M
|
-$2,000.00
|
$6.24 M
|
$3.00 M
|
$713,000.00
|
$497,000.00
|
$906,000.00
|
| Income Before Tax |
-$51.93 M
|
-$92.56 M
|
-$282.84 M
|
-$383.46 M
|
-$286.29 M
|
-$171.90 M
|
-$76.91 M
|
-$135.75 M
|
-$60.72 M
|
-$37.03 M
|
| Income Before Tax Ratio |
-0.27
|
-0.32
|
-1.32
|
-1.3
|
-0.85
|
-0.83
|
-0.43
|
-88.43
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$13.45 M
|
-$37.97 M
|
-$33.59 M
|
-$6.63 M
|
-$28.34 M
|
-$2.80 M
|
-$901,000.00
|
-$510,000.00
|
-$206,000.00
|
| Net Income |
-$51.93 M
|
-$106.01 M
|
-$244.87 M
|
-$349.87 M
|
-$279.66 M
|
-$171.90 M
|
-$76.91 M
|
-$135.75 M
|
-$60.72 M
|
-$37.03 M
|
| Net Income Ratio |
-0.27
|
-0.36
|
-1.15
|
-1.18
|
-0.83
|
-0.83
|
-0.43
|
-88.43
|
0
|
0
|
| EPS |
-0.28 |
-0.58 |
-1.48 |
-2.53 |
-2.36 |
-1.47 |
-1.77 |
-3.6 |
-2.29 |
-2.4 |
| EPS Diluted |
-0.28 |
-0.58 |
-1.48 |
-2.53 |
-2.36 |
-1.47 |
-1.77 |
-3.6 |
-2.29 |
-2.4 |
| Weighted Average Shares Out |
$187.47 M
|
$182.78 M
|
$165.95 M
|
$138.46 M
|
$118.40 M
|
$116.89 M
|
$43.50 M
|
$37.72 M
|
$26.47 M
|
$15.41 M
|
| Weighted Average Shares Out Diluted |
$187.47 M
|
$182.78 M
|
$165.95 M
|
$138.46 M
|
$118.40 M
|
$116.89 M
|
$43.50 M
|
$37.72 M
|
$26.47 M
|
$15.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
